This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Picks Ahead of Key Congressional Hearing on Marijuana Laws
by Nalak Das
Several economists and market researchers believe that the four bills may pave the way for marijuana ETFs, which are likely to attract billions of dollars in investment.
Scotts Miracle-Gro Hits 52-Week High: What's Driving it?
by Zacks Equity Research
Upbeat outlook for fiscal 2019 is driving Scotts Miracle-Gro's (SMG) shares.
Scotts Miracle-Gro (SMG) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Scotts Miracle-Gro (SMG) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Canopy Growth, GW, Scotts Miracle-Gro, Cronos and Aurora
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth, GW, Scotts Miracle-Gro, Cronos and Aurora
Breakthrough in U.S. Marijuana Industry: 5 Likely Gainers
by Nalak Das
The marijuana industry has strong potential especially after its legalization for recreational and medicinal use.
The Zacks Analyst Blog Highlights: Materion, SSR, Axalta, Air Products and Scotts Miracle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Materion, SSR, Axalta, Air Products and Scotts Miracle
5 Top Basic Materials Stocks to Buy on June Turnaround
by Nalak Das
Despite the trade tussle and threat of a global economic slowdown, basic materials is flourishing primarily on strong market sentiment courtesy of interest rate cut signal by the Fed.
Scotts Miracle-Gro (SMG) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Scotts Miracle-Gro (SMG) have what it takes? Let's find out.
Scotts Miracle-Gro (SMG) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Scotts Miracle-Gro (SMG) have what it takes to be a top stock pick for momentum investors? Let's find out.
ScottsMiracle-Gro (SMG) Provides Revised View for Fiscal 2019
by Zacks Equity Research
Scotts Miracle-Gro (SMG) projects adjusted EPS in the range of $4.20-$4.40 for fiscal 2019 compared with the prior guidance of $4.10-$4.30.
Scotts (SMG) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Scotts (SMG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA to Hold First Public Hearing on Cannabis: 5 Likely Gainers
by Nalak Das
Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.
Fertilizers Industry Outlook: Near-Term Prospects Bleak
by Nilanjan Gupta
Renewed trade war fears and persistent softness in commodity prices cast a pall over the Zacks Fertilizer industry.
Scotts Miracle-Gro (SMG) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Scotts Miracle-Gro (SMG) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Technology and Ubisoft Entertainment
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Technology and Ubisoft Entertainment
Buy Marijuana Stocks, Tilray & Aurora Cannabis, Before Earnings?
by Benjamin Rains
The legal marijuana industry is still in the early stages, so let's see if investors should consider buying some pure-play marijuana stocks heading into earnings.
5 Best Stocks to Buy for Sinful Gains This May
by Tirthankar Chakraborty
Sin stocks provide a stable stream of consumers, irrespective of market conditions, which leads to higher margins and solid profits.
Century Aluminum (CENX) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Century Aluminum's (CENX) shipments in Q1 benefit from restart of the Hawesville facility.
Why Scotts Miracle-Gro (SMG) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Scotts Miracle-Gro (SMG) have what it takes? Let's find out.
FMC Beats Earnings & Sales Estimates in Q1, Raises 2019 View
by Zacks Equity Research
FMC Corporation's (FMC) Q1 results gain from contributions of volume and price, partly offset by currency headwinds.
Scotts Miracle-Gro (SMG) Tops Q2 Earnings & Sales Estimates
by Zacks Equity Research
Scotts Miracle-Gro's (SMG) U.S. Consumer unit witnesses double-digit growth in consumer purchases in fiscal Q2.
Scotts Miracle-Gro (SMG) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Scotts (SMG) delivered earnings and revenue surprises of 6.43% and 2.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Scotts Miracle-Gro (SMG) in Q2 Earnings?
by Zacks Equity Research
Scotts Miracle-Gro's (SMG) fiscal Q2 results to benefit from growth in the Hawthorne segment.
Scotts Miracle-Gro (SMG) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Scotts (SMG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.